308 related articles for article (PubMed ID: 16678903)
1. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.
Denning DW; Marr KA; Lau WM; Facklam DP; Ratanatharathorn V; Becker C; Ullmann AJ; Seibel NL; Flynn PM; van Burik JA; Buell DN; Patterson TF
J Infect; 2006 Nov; 53(5):337-49. PubMed ID: 16678903
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of micafungin for chronic pulmonary aspergillosis.
Izumikawa K; Ohtsu Y; Kawabata M; Takaya H; Miyamoto A; Sakamoto S; Kishi K; Tsuboi E; Homma S; Yoshimura K
Med Mycol; 2007 May; 45(3):273-8. PubMed ID: 17464848
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of micafungin alone or in combination against systemic murine aspergillosis.
Luque JC; Clemons KV; Stevens DA
Antimicrob Agents Chemother; 2003 Apr; 47(4):1452-5. PubMed ID: 12654692
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis.
Ikeda F; Wakai Y; Matsumoto S; Maki K; Watabe E; Tawara S; Goto T; Watanabe Y; Matsumoto F; Kuwahara S
Antimicrob Agents Chemother; 2000 Mar; 44(3):614-8. PubMed ID: 10681327
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan.
Kohno S; Masaoka T; Yamaguchi H; Mori T; Urabe A; Ito A; Niki Y; Ikemoto H
Scand J Infect Dis; 2004; 36(5):372-9. PubMed ID: 15287383
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis.
Clemons KV; Stevens DA
Med Mycol; 2006 Feb; 44(1):69-73. PubMed ID: 16805095
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis.
Matsumoto S; Wakai Y; Nakai T; Hatano K; Ushitani T; Ikeda F; Tawara S; Goto T; Matsumoto F; Kuwahara S
Antimicrob Agents Chemother; 2000 Mar; 44(3):619-21. PubMed ID: 10681328
[TBL] [Abstract][Full Text] [Related]
8. [Antifungal activity and clinical efficacy of micafungin sodium (Funguard)].
Ikeda F
Nihon Yakurigaku Zasshi; 2003 Oct; 122(4):339-44. PubMed ID: 14501170
[TBL] [Abstract][Full Text] [Related]
9. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis.
Kontoyiannis DP; Ratanatharathorn V; Young JA; Raymond J; Laverdière M; Denning DW; Patterson TF; Facklam D; Kovanda L; Arnold L; Lau W; Buell D; Marr KA
Transpl Infect Dis; 2009 Feb; 11(1):89-93. PubMed ID: 18983417
[TBL] [Abstract][Full Text] [Related]
10. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Roussillon K; Hemmings M; Lyman CA; Sein T; Bacher J; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2002 Jun; 46(6):1857-69. PubMed ID: 12019101
[TBL] [Abstract][Full Text] [Related]
11. Micafungin: a therapeutic review.
Higashiyama Y; Kohno S
Expert Rev Anti Infect Ther; 2004 Jun; 2(3):345-55. PubMed ID: 15482200
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of micafungin for the treatment of patients with proven or probable invasive aspergillosis: A non-comparative, multicenter, phase IV, open-label study.
Ji Y; Song Y; Zhou F; Liu T; Jiang M; Zhao X; Huang X
Medicine (Baltimore); 2017 Dec; 96(52):e9443. PubMed ID: 29384927
[TBL] [Abstract][Full Text] [Related]
13. Role of micafungin in the antifungal armamentarium.
Ikeda F; Tanaka S; Ohki H; Matsumoto S; Maki K; Katashima M; Barrett D; Aoki Y
Curr Med Chem; 2007; 14(11):1263-75. PubMed ID: 17504145
[TBL] [Abstract][Full Text] [Related]
14. Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice.
Vehreschild JJ; Cornely OA
Future Microbiol; 2006 Aug; 1(2):161-70. PubMed ID: 17661660
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.
Petraitis V; Petraitiene R; Sarafandi AA; Kelaher AM; Lyman CA; Casler HE; Sein T; Groll AH; Bacher J; Avila NA; Walsh TJ
J Infect Dis; 2003 Jun; 187(12):1834-43. PubMed ID: 12792859
[TBL] [Abstract][Full Text] [Related]
16. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.
Wiederhold NP; Lewis JS
Expert Opin Pharmacother; 2007 Jun; 8(8):1155-66. PubMed ID: 17516879
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients.
Cesaro S; Giacchino M; Locatelli F; Spiller M; Buldini B; Castellini C; Caselli D; Giraldi E; Tucci F; Tridello G; Rossi MR; Castagnola E
BMC Infect Dis; 2007 Apr; 7():28. PubMed ID: 17442100
[TBL] [Abstract][Full Text] [Related]
18. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid.
Okugawa S; Ota Y; Tatsuno K; Tsukada K; Kishino S; Koike K
Scand J Infect Dis; 2007; 39(4):344-6. PubMed ID: 17454899
[TBL] [Abstract][Full Text] [Related]
19. Effective blood concentration of micafungin for pulmonary aspergillosis.
Shimoeda S; Ohta S; Kobayashi H; Yamato S; Sasaki M; Kawano K
Biol Pharm Bull; 2006 Sep; 29(9):1886-91. PubMed ID: 16946503
[TBL] [Abstract][Full Text] [Related]
20. [Efficacies and clinical roles of new antifungal agents].
Tokimatsu I; Kadota J
Nihon Ishinkin Gakkai Zasshi; 2006; 47(3):155-9. PubMed ID: 16940948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
